May. 5 at 8:46 PM
$EXEL From zacks:
Exelixis (EXEL - Free Report) came out with quarterly earnings of
$0.87 per share, beating the Zacks Consensus Estimate of
$0.75 per share. This compares to earnings of
$0.62 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +15.55%. A quarter ago, it was expected that this drug developer would post earnings of
$0.77 per share when it actually produced earnings of
$0.94, delivering a surprise of +22.08%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
